Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Chuwei Yu"'
Autor:
Yunxia Dong, Chuwei Yu, Ningning Ma, Xiaoding Xu, Qian Wu, Henglei Lu, Likun Gong, Jing Chen, Jin Ren
Publikováno v:
Molecular Biomedicine, Vol 3, Iss 1, Pp 1-15 (2022)
Abstract Lipotoxicity induced by the overload of lipid in the liver, especially excess free cholesterol (FC), has been recognized as one of driving factors in the transition from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH
Externí odkaz:
https://doaj.org/article/1954892f1a9048fc8f6f9164100c5411
Publikováno v:
Land, Vol 12, Iss 9, p 1662 (2023)
Analysis of spatial patterns and driving factors of different ethnic villages under regional integration is important for the conservation and development of ethnic villages. This article takes seven multi-ethnic villages in the Dadu River Basin of G
Externí odkaz:
https://doaj.org/article/8b9c7fa95a4b4f08a9301e25c265b1ef
Autor:
Rongrong Tan, Jiayang Li, Lu Liu, Qian Wu, Lei Fan, Ningning Ma, Chuwei Yu, Henglei Lu, Xuemei Zhang, Jing Chen, Likun Gong, Jin Ren
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 24, p 15931 (2022)
Non-alcoholic fatty liver disease (NAFLD) is a chronic metabolic disease manifested in hepatic steatosis, inflammation, fibrosis, etc., which affects over one-quarter of the population around the world. Since no effective therapeutic drugs are availa
Externí odkaz:
https://doaj.org/article/abbfca96e6114926a3684f716cf0953f
Autor:
Ningning Ma, Aijun Hou, Xiangyu Pan, Fuguang Sun, Xiaoding Xu, Chuwei Yu, Rongtao Lai, Ruimin Huang, Likun Gong, Qing Xie, Jing Chen, Jin Ren
Publikováno v:
International Journal of Biological Sciences; 2023, Vol. 19 Issue 11, p3456-3471, 16p
Publikováno v:
Molecular biology reports. 49(10)
Nonalcoholic fatty liver disease (NAFLD) is one of the most common metabolic diseases and closely associated with lipid disorder. Mitochondrion has been recognized to play a key role in lipid metabolism as the main site of energy metabolism in cells,
Autor:
Ningning Ma, Chuwei Yu, Weiwen Kong, Likun Gong, Jing Chen, Jin Ren, Yunxia Dong, Xiaoding Xu
Publikováno v:
Metabolism: clinical and experimental. 119
Background Reducing serum low-density lipoprotein cholesterol (LDL-C) in hyperlipemia is recognized as an effective strategy to minimize the risk of atherosclerotic cardiovascular disease (ASCVD). MiR-337-3p has already been discovered to play regula
Publikováno v:
Pharmacological Research. 167:105562
PCSK9 has emerged as a promising new therapeutic target for hyperlipidemia. The efficacy of PCSK9 siRNA in clinic trials clues the feasibility of exploring more PCSK9 inhibitors based on genetic inhibition in the treatment of hyperlipidemia. MicroRNA